AZR

3.6653.81%

Adial Pharmaceuticals Changes Name to Azora Therapeutics

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Adial Pharmaceuticals changed its name to Azora Therapeutics, focusing on treatments for inflammatory diseases. * Common stock is expected to begin trading on Nasdaq under ticker AZR on October 29, 2026. * Matt Davidson was appointed president and chief executive officer to lead the new executive team. * Lead candidate AT177, an oral, colon-targeted AhR agonist for ulcerative colitis, is expected to enter Phase 1 trials in first-half 2027. * Current cash and cash equivalents are expected to fund operational plans into 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610281602PRIMZONEFULLFEED9855512) on October 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.